Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(10 sites)

Spain

Hospital Germans Trias i Pujol (ICO BADALONA), Badalona

H. Clinic de Barcelona, Barcelona

H. 12 de Octubre, Madrid

H. Ramón y Cajal, Madrid

Clinica Universidad de Navarra, Pamplona

Hospital Clinico Universitario Salamanca, Salamanca

H. Marqués de Valdecilla, Santander

C H Santiago de Compostela, Santiago de Compostela

Complejo Hosp. Regional Virgen del Rocío, Seville

Hospital Universitario y Politécnico La Fe de Valencia, Valencia